Clinical Trials
24 trialsNCT03866382 2026-06-03
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02496208 2026-05-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07384416 2026-05-08
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05946993 2026-05-01
LIAM Mc
University College Cork
Phase NA Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07378670 2026-04-15
DEPECA-2
University Hospital Tuebingen
Phase NA Recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07518979 2026-04-09
MH-Penile-002
West China Hospital
Phase 2 Not yet recruiting
NCT07054307 2026-04-07
MH-Penile-001
West China Hospital
Phase 1 Recruiting
NCT04708470 2026-04-06
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT07497919 2026-03-27
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT05686226 2026-02-27
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03391479 2025-12-18
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
University Health Network, Toronto
Phase 2 Active not recruiting
NCT06104618 2025-12-11
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
Phase 2 Recruiting
NCT06353906 2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05526989 2025-12-04
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT07101822 2025-08-03
BRAVA PENILE
Hospital Israelita Albert Einstein
Phase 2 Not yet recruiting
NCT02817958 2025-06-26
MEGACEP
UNICANCER
Phase 2 Active not recruiting